Disability News and Research

RSS

Employers looking for ways to reduce high blood pressure in the workplace

A group of nine Kansas City employers, their broker consultant Lockton Companies, the Kansas Department of Health and Environment, Centers for Disease and Prevention Control, and Thomson Reuters are looking for ways to reduce high blood pressure or hypertension in the workplace.

22 Apr 2011

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.

21 Apr 2011

NHATS to begin enrollment for study on improving quality of life among the elderly

21 Apr 2011

Military personnel with TBI should receive adequate protein and calories immediately after trauma

To help alleviate the effects of severe traumatic brain injury (TBI), the U.S. Department of Defense should ensure that all military personnel with this type of injury receive adequate protein and calories immediately after the trauma and through the first two weeks of treatment, says a new report from the Institute of Medicine.

21 Apr 2011

Enrollment begins in ‘National Health and Aging Trends’ study

The National Health and Aging Trends Study (NHATS), led by researchers at the Johns Hopkins Bloomberg School of Public Health, will begin enrolling study participants to examine how current and future aging populations can lead fuller, healthier lives. The study, which begins data collection on May 1, 2011, is supported by the National Institute on Aging and is designed to help researchers understand changes in health and functioning among seniors, as well as the social and economic consequences of health and aging for individuals, families and society.

20 Apr 2011

SafeMinds calls for immediate vaccine safety studies in autistic children

Alison MacNeil issued the following statements today regarding vaccines.

19 Apr 2011

New research: 56% of Canadians with AF do not fear having fatal stroke

New research reveals more than half of Canadians living with atrial fibrillation do not fear having a stroke, despite AF-related strokes being more severe, debilitating and twice as likely to be fatal.

19 Apr 2011

Intellectual disability may have genetic origin, but is not hereditary

Mutations in a group of genes associated with brain activity frequently cause intellectual disability, according to a study led by scientists affiliated with the University of Montreal and the research centre at the Centre hospitalier universitaire Sainte-Justine. Intellectual disability is a severe handicap that affects between one and two percent of children worldwide. It can often be attributed to genetic causes, but the specific genes involved were mostly unknown.

18 Apr 2011

Researchers discover strategy that promotes new blood vessel formation

Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.

18 Apr 2011

Scientist discovers new molecular mechanism underlying asthma, COPD

Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease and several other lung conditions.

18 Apr 2011

Women experience more severe and frequent domestic violence than men

Domestic violence knows no boundaries: cultural, socio-economic, religious, level of education, gender or age. It can occur in any relationship and to anyone, but especially to women. In fact, roughly 25 percent of women will become a victim at one time or another during her lifetime.

16 Apr 2011

Roundup: Medicaid bill headed for Florida Senate floor; Texas nursing home funding vulnerable in state budget

The Texas Legislature is faced with a budget challenge that has pitted the Republican majority's desire to cut government spending against a vulnerable target: nursing homes.

16 Apr 2011

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

Boehringer Ingelheim's novel oral anticoagulant dabigatran etexilate, received a positive opinion from the European Medicines Agency's medicinal committee today.

16 Apr 2011

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.

15 Apr 2011

Cerapedics announces i-FACTOR biologic bone graft study results in PLIF spine surgery

Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced the results of a prospective, randomized, controlled trial of its i-FACTOR biologic bone graft for patients undergoing posterior lumbar interbody fusion spine procedures.

12 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011